IFARMA Contract Research Company

History

2021: Doctis bought Ifarma

November 19, 2021 it became known about the sale of a controlling stake in the contract research company "Ifarma" to the service of online consultations of doctors and medical support of patients Doktis"," founded by the general director and main owner of the group "."Mother and child Mark Kurzer

According to RBC with reference to the materials of the Federal Antimonopoly Service (FAS), the regulator issued permission to conduct this transaction. Doctis also intends to acquire 51% of Ifarma LLC, based in Skolkovo ( as well as Doctis). The financial terms of the agreement are not disclosed.

Doctis acquired Ifarma

It is noted that the combined team will create a digital clinical research platform that will enter the Doctis medical ecosystem. The platform will make it possible to organize communication between the patient and the doctor remotely, for example, for online consultation or adjustment of medication. And the processing of the obtained data, their layout, comparison of the results of research will be carried out using artificial intelligence.

According to the head of the DSM Group, Sergei Shulyak, for Mark Kurzer, investing in Ifarma is an opportunity to diversify the business, as well as entering the pharmaceutical production market. Nikolai Bespalov, Director of Development at RNC Pharma, also suggests that this is a strategic investment aimed at working in the pharmaceutical sector.

The representative of Doctis, in a conversation with RBC, noted that the coronavirus pandemic COVID-19 indicated the need to accelerate and reduce the cost of introducing new drugs to the market.

Earlier in 2021, Ifarma received a consecutive NITsEM named after N.F. Gamalei, the developer of the anti-virus vaccine Sputnik V, to conduct a clinical study of the effectiveness of the TB vaccine GamTBvak. The contract value is 54.3 million rubles.^[1]

Notes